Table 2.
Model of care
| MDR-TB | DS-TB | |
|---|---|---|
| 44 | 1134 | |
| Mean (95% CI) | Mean (95% CI) | |
| Hospitalisation | ||
| Hospitalized at time of interview, N (%) | 18 (41.9%) | 74 (6.53%) |
| Previously hospitalized during current phase, N (%) | 7 (16.7%) | 125 (11.0%) |
| Times hospitalized during current phase, Mean (95% CI) | 1.64 (0.83–2.45) | 1.14 (1.04–1.23) |
| Mean duration (days) hospitalized during current phase (95% CI) | 91.4 (0–199.2) | 12.9 (10.1–15.8) |
| Median duration (days) hospitalized during current phase (IQR) | 30 (26–102) | 7 (5–14) |
| Ambulatory care | ||
| Number of visits per episode: total (95% CI) | 1093.4 (917–1269.8) | 51.2 (42.1–60.3) |
| Number of visits: DOT (95% CI) | 614.5 (555.6–673.5) | 167.6 (157.7–177.5) |
| Number of visits: follow-up (95% CI) | 10.9 (0–22.5) | 3.7 (3.1–4.3) |
| Number of visits: drug pick-up (95% CI) | 569.1 (529.9–608.3) | 9.1 (7.7–10.5) |
| Number of visits pre-diagnosis (95% CI) | 1.6 (0.9–2.2) | 1.1 (1.1–1.2) |
| Proportion of first visits to primary health facilities | 5 (84.2%) | 189 (39%) |
| Proportion of first visits from private facilities | 2 (28.8%) | 159 (32.8%) |
| Proportion of TB diagnoses made at private or NGO facility | 2 (5%) | 300 (26.5%) |
| Treatment duration | ||
| Treatment duration: intensive phase, weeks Mean (95% CI) | 7 (6.1–7.9) | 2 (2–2.1) |
| Treatment duration: continuation phase, weeks Mean (95% CI) | 14.8 (12.8–16.8) | 4.1 (4.1–4.1) |
| Treatment delay (among new patients in intensive phase) | 6 | 486 |
| Weeks of treatment delay Mean (95% CI) | 9.5 (3.4–15.7) | 9.9 (8.1–11.8) |
| Proportion of patients with delay > 28 days (%) | 3 (50.0%) | 223 (45.9%) |